Form 4: Lixte Biotechnology Director Regina Brown Reports Stock Option Grants
SEC Form 4 Filing
Regina Brown, a director of Lixte Biotechnology Holdings, Inc., reported the acquisition of stock options on June 30, 2024.
Summary
- On July 2, 2024, Regina Brown, a director of Lixte Biotechnology Holdings, Inc., filed a Form 4.
- The report details the grant of stock options to purchase common stock.
- On June 30, 2024, Brown was granted options to purchase 10,000 shares at an exercise price of $2.37, vesting quarterly starting September 30, 2024.
- Additionally, Brown received options to purchase 4,904 shares at $2.37, vesting immediately, in lieu of quarterly cash compensation.
- Brown also holds previously granted options with varying exercise prices and expiration dates.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing, and the sentiment is neutral.
Positives
- The grant of stock options to a director aligns their interests with those of shareholders.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders.
Stakeholder Impact
- Shareholders may view the option grants as an incentive for the director to act in their best interests.
Key Dates
| Date | Description |
|---|---|
| 05/11/2021 | Date of previously granted options with an exercise price of $28.00, expiring 05/11/2026 |
| 06/30/2021 | Date of previously granted options with an exercise price of $30.30, expiring 06/30/2026 |
| 06/30/2022 | Date of previously granted options with an exercise price of $7.45, expiring 06/30/2027 |
| 06/30/2023 | Date of previously granted options with an exercise price of $5.88, expiring 06/30/2028 |
| 06/30/2024 | Date of transaction: Grant of options to purchase 10,000 shares at $2.37, vesting quarterly, and 4,904 shares at $2.37, vesting immediately. |
| 06/30/2029 | Expiration date of options to purchase 10,000 shares at $2.37, vesting quarterly. |
| 07/02/2024 | Date of Form 4 filing. |
| 09/30/2024 | Start date for quarterly vesting of 10,000 options granted on June 30, 2024. |
Keywords
stock options, Form 4, director, Lixte Biotechnology, LIXT, Regina Brown, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.